Menu

  • Reimbursement
  • Medtronic Academy

    • Treating painful bone tumors

    Pain relief in as few as three days1

    Perform faster ablations with more procedural flexibility and power. The OsteoCool™ radiofrequency (RF) ablation system is cooled RF ablation technology. It treats painful bone tumors, including benign and painful metastatic lesions. The system’s algorithms are designed to perform optimally in bone, allowing you to overcome challenges through a wide range of ablation scenarios, letting you treat patients confidently and consistently.

    OsteoCool™ 2.0 RF ablation system

    The OsteoCool™ 2.0 RF ablation system helps you deliver optimal care for your patients, treating painful bone tumors with internally-cooled probes and now featuring faster ablations,†,2 four probes, and more power.3-5 

    See the system

    OsteoCool™ clinical outcomes

    The OsteoCool™ post-market clinical study (OPuS One) is a multicenter study that collected real-world evidence on the efficacy and safety of OsteoCool™ RF ablation. Twelve-month data show outcomes in 206 patients treated with OsteoCool™ RF ablation, including pain relief and improved quality of life in as little as three days.1

    See the study (open in new window)

    OsteoCool™ RF ablation system

    OsteoCool™ is our legacy system for treating painful bone tumors. 

    Learn more
    The OsteoCool™  radiofrequency (RF) ablation system uses simultaneous, dual-probe capabilities and algorithms to treat painful bone tumors.

    Talk to a Medtronic representative.

    Education, training, and events

    Explore courses, videos, and educational opportunities for pain physicians.

    Medtronic Academy

    † Bench testing may not be indicative of clinical results.

    1. Levy J, David E, Hopkins T, et al. Radiofrequency Ablation Provides Rapid and Durable Pain Relief for the Palliative Treatment of Lytic Bone Metastases Independent of Radiation Therapy: Final Results from the OsteoCool Tumor Ablation Post-Market Study. Cardiovasc Intervent Radiol. 2023;46(5):600-609. doi:10.1007/s00270-023-03417-x
    2. Based on internal data: ETR 30101200, OsteoCool™ 2.0 lesion validation test report, 20 samples. 2023.
    3. Clarivate Interventional Oncology Devices Market.
    4. Insights United States report, December 2022. Stryker OptaBlate™* RF generator system IFU 700001075365 Rev-AC.
    5. Merit MetaSTAR™* RF generator IFU 403321001_001.